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The anti-apoptotic proteins Bcl-XL and Bcl-2 are abundantly expressed in hematopoietic stem cells and/
or progenitor cells. Furthermore, leukemic cells expressing these proteins are enriched in minimal
residual disease cell populations. This prompted us to test the BH3-mimetic compound ABT-737 for its
ability to eradicate putative leukemic stem cells. ABT-737 demonstrated potent cytotoxic effects in all
patient samples tested. The efﬁcacy of ABT-737 against AML blasts and the primitive CD34þ/CD38
population was equal and independent of sensitivity to cytarabine/daunorubicin. These results, together
with previously reported synergistic effects of ABT-737 with chemotherapeutics make BH3-mimetics
promising candidates for future AML treatment regimens.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
1. Introduction
Acute myeloid leukemia (AML) is a biologically heterogeneous
group of related diseases in urgent need of better therapeutic options.
Despite sensitivity to initial treatment, 70–90% of elderly patients
relapse within 5 years. There is accumulating evidence that a small
population of primitive cells, called putative leukemic stem cells
(pLSCs), resistant to treatment in bone marrow niche sites is respon-
sible for disease relapse [1,2]. Anti-apoptotic Bcl-2 proteins have long
been known to play a major role in the long-term survival of
hematopoietic stem and progenitor cells [3]. Pluripotent hematopoi-
etic stem cells identiﬁed as CD34þ/lin/CD38 abundantly express
Bcl-XL, while progenitor cells (CD34þ) produce high amounts of
Bcl-2 [3]. Additionally, treatment with chemotherapeutics have been
shown to induce anti-apoptotic Bcl-2 protein expression and minimal
residual disease cells also express high levels of Bcl-2/Bcl-XL [4].
Despite this long-known feature of primitive hematopoietic cells
and pLSCs, the potential of the recently developed Bcl-2/Bcl-XL/Bcl-W
inhibitor, ABT-737 in eradicating AML putative leukemic stem cells has
not been thoroughly examined. In this study, we show that ABT-737 is
potent and equally effective in killing both AML blasts and CD34þ/
CD38 progenitors. The effect did not depend on the source of the
AML cells (bone marrow or peripheral blood), or the resistance of the
pLSCs to the mainstream chemotherapeutic drug combination of
cytarabine (AraC) and daunorubicin (DnR).
2. Materials and methods
2.1. Patient samples
AML patient's bone marrow aspirates and peripheral blood
samples were kindly provided by Department of Hematology,
University Hospital Galway. Mononuclear cells (MNCs) were sepa-
rated by standard ﬁcoll separation protocol and then cultured
ex vivo as described before [5].
2.2. Ethical approval
The project was approved by the Galway University Hospital
ethics committee. Informed consent was obtained from patients
before collection of material.
2.3. Cell lines and ex vivo culture system
The human stromal cell line HS-5 (expressing GFP) was cultured in
DMEM supplemented with 10% FBS. Patient-derived MNCs were
seeded on HS-5 cells of 70% conﬂuency at a concentration of 3105
cells/well for 24 h prior to treatment. Cells were treated with ABT-737
or clinically relevant dosages of cytarabineþdaunorubicin combina-
tion for 24 h (in a molar concentration ratio of 3:1).
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2.4. Flow cytometry
MNCs were incubated with anti-CD34 and anti-CD38 antibodies
(BD Bioscience, San Diego, USA) in PBS/1% BSA (Sigma) following the
manufacturer's instructions. After washing off unbound antibodies
cells were stained with 2 μM of 7-aminoactinomycin D (7-AAD; Life
Technologies) to label the dead cell population for 15 min at room
temperature. Samples were analyzed on a BD Canto II ﬂow cytometer
by collecting 105 events. HS-5 cells were excluded by gating out
GFPþ/FSСhigh events. Statistical analysis and data visualization were
performed using GraphPad Prism software (GraphPad Software inc.,
La Jolla, USA).
3. Results and discussion
ABT-737 is a BH3-mimetic targeting Bcl-2, Bcl-XL and Bcl-W.
The aim of the experiments was to test whether inhibition of Bcl-2
and Bcl-XL using ABT-737 can eradicate the CD34þ/CD38 AML
cell population. Bone marrow MNCs from patients (Table 1) were
Table 1
List of AML patients' bone marrow and blood samples used.
Patient
number
Sample type
(PB/BM)
AML type Remarks
1 BM Refractory cytopenia with excess of blasts II (15%), normal karyotype, FLT3 positive Palliative care
2 BM, PB Acute myeloid leukemia with multilineage dysplasia, complex karyotype, FLT3 negative Treatment: clofarabine-refractory
3 BM Acute myeloid leukemia normal karyotype, FLT3 positive Treatment: daunorubicin and cytarabine –
complete remission
4 BM, PB Acute myeloid leukemia, not otherwise categorized, Acute myeloid leukemia without
maturation, normal karyotype, FLT3 negative
Treatment: daunorubicin and cytarabine –
refractory
Note: samples were received upon diagnosis.
Fig. 1. ABT-737 has a potent cytotoxic effect on bone marrow-derived AML pLSCs. Bone marrow-derived primary AML cells were cultured on a stromal-feeder layer for 24 h
and then treated with 30 nM and 300 nM of ABT-737 for 24 h. AML cell viability was evaluated using7-AAD staining and ﬂow cytometry. (A) The cytotoxic effect of ABT-737
on the overall blast population. The graph shows the percentage of live cells for each sample. (B) ABT-737 is equally efﬁcient in eradicating AML pLSCs. The graph shows the
percentage of the CD34þ/CD38 cells within the surviving AML cell population in each sample. E Horizontal lines indicate mean values. Different shapes indicate data-points
corresponding to particular patient samples (Patients cross-referencing with Table 1: Patient 1 (○), Patient 2 (■), Patient 3 (), Patient 4 (□)).
Fig. 2. AML cells show variable sensitivity to the combination of cytarabine and daunorubicin. Bone marrow primary AML cells were cultured on a stromal-feeder layer and
then were treated with 4.5 μM cytarabine (AraC)þ1.35 μM daunorubicin (DnR) for 24 h. AML cell viability was evaluated using 7-AAD staining and ﬂow cytometry. (A) The
cytotoxic effect of AraCþDnR on the overall blast population. The graph shows the percentage of live cells for each sample. (B) Treatment with AraCþDnR leads to
enrichment of the CD34þ/CD38 cell population in the surviving fraction. The graph shows the percentage of the CD34þ/CD38 cells within the surviving AML cell
population in each sample. Different shapes indicate data-points corresponding to different patient samples. (Patients cross-referencing with Table 1: Patient 1 (○), Patient 2
(■), Patient 3 (●), Patient 4 (□)).
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cultured on stromal-feeder layer for 24 h and then treated with
dosages of ABT-737 of 30 nM and 300 nM. The co-culture system
has been optimized for supporting the survival of AML cells
ex vivo and to model features of the bone marrow microenviron-
ment that drive drug-resistance [8]. The dose range was selected
based on the in vitro effect of ABT-737 on secondary AML cell lines
[8]. The resting cell viability of the patient samples was between
60% and 90% after 24 h of stromal-feeder co-culture. ABT-737
potently killed the AML cells in all samples with the 300 nM dose
causing a 75% average loss in viability (Fig.1A). Similar results were
obtained from a parallel study with ALL patient samples [data not
shown].
-
To check the activity of ABT-737 against pLSCs, the proportion of
CD34þ/CD38 cells was evaluated within the surviving cell popula-
tion. The relative percentage of pLSCs did not increase in response to
ABT-737 treatment highlighting that the CD34þ/CD38 pLSCs-
containing population has the same sensitivity to ABT-737 as the
more differentiated AML blasts. Resistance of pLSCs to ABT-737
would have resulted in the relative enrichment of the CD34þ/
CD38 pLSCs compartment (Fig. 1B). Of note, the two samples that
carried Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-
ITD) mutation (patients 2 and 4) showed higher percentage of pLSCs
within the sample, but these pLSCs were also sensitive to ABT-737.
On the contrary, AraCþDnR combination treatment showed variable
efﬁcacy on the AML blasts, with enrichment of the CD34þ/CD38
pLSCs population in most samples (Fig. 2A and B). Finally, the efﬁcacy
of ABT-737 on bone marrow-residing versus disseminated AML cells
was compared using matched patient samples. The bone marrow-
derived and peripheral blood-derived cells were cultured and treated
as described above and overall cell death, and cell death within the
CD34þ/CD38 LIC compartment was determined. ABT-737 showed
comparable efﬁcacy on disseminated AML cells, including the circu-
lating pLSCs population (Fig. 3A and B).
The current data, in line with previously published studies, clearly
show that ABT-737 demonstrates efﬁcacy against AML blasts com-
parable or superior to the activity of traditional drugs in current
clinical use, such as AraC and [9]. Moreover, several studies have
shown that combination of ABT-737 with chemotherapeutics, such as
daunorubicin [6] and 5-Azacytidine [7] have a synergistic cytotoxic
effect on AML blast cells. However, no studies have focused on
examining the effect ABT-737 on the pLSCs subpopulation and the
potential effect of the bone marrow microenvironment on ABT-737
resistance of pLSCs has not been sufﬁciently studied either. This is of
key importance as the interaction with stromal bone marrow
components can induce the expression of Bcl-2 and Bcl-XL in the
AML cells. Our ﬁndings prove that the pLSC-containing CD34þ/
CD38 population can be efﬁciently targeted via inhibition of Bcl-2
and Bcl-XL even in the presence of bone marrow stroma which was
able to provide resistance against AraC and DnR.
It has to be noted that in some AMLs, especially the ones that
harbor a FLT3-ITD mutation, the LICs can express very high levels
of another anti-apoptotic Bcl-2 family member, Mcl-1 that
ABT-737 or the orally bioavailable ABT-737 derivative, ABT-263
cannot inhibit [10]. The FLT3-ITD positive samples studied here did
not show resistance to ABT-737, but testing of a larger sample
cohort would be necessary to conﬁrm these ﬁndings. Eradication
of high Mcl-1 expressing AML pLSCs is thus likely to require a
combination of BH3-mimetics with complementary anti-apoptotic
Bcl-2 protein binding proﬁle, such as the combination of ABT-263
with Mcl-1-targeting BH3-mimetics, for example BIMS2A or MCL-
1 SAHB (currently in pre-clinical evaluation). Other, non-BH3
motif-like drugs which are also able to target Mcl-1 are also being
developed. One such example is the small molecule drug S1 that
inhibits Mcl-1 by causing induction of the pro-apoptotic BH3-only
Bcl-2 family member Noxa, the unique BH3-binding partner and
inhibitor of Mcl-1.
The current progress in the development of BH3-mimetics and
the emerging results of clinical trials corroborate the potential of
strategies targeting anti-apoptotic Bcl-2 proteins to kill AML pLSCs
and achieve a long-lasting cure.
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Fig. 3. ABT-737 has an equally high cytotoxic efﬁcacy in disseminated AML pLSCs. Bone marrow and peripheral blood-derived primary AML cells from 2 matching patients
were cultured and treated and the percentage of surviving cells determined as described before. (A) Viability of bone marrow-derived and peripheral blood-derived overall
AML population after exposure to ABT-737. (B) The percentage of CD34þ/CD38 cells within the surviving population of leukemic blasts in both bone marrow and peripheral
blood-derived matching sample sets showing equal efﬁcacy of ABT-737 compound against AML blasts and pLSCs. The % of pLSCs within live AML cell population was
evaluated as a number of CD34þ/CD38-7AAD events. Different shapes indicate data-points corresponding to different patient samples. (Patients cross-referencing with
Table 1: Patient 2 (■), Patient 4 (□)).
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